Table 1.
Baseline Characteristics
| Variable | Measure |
|---|---|
| Patient characteristics (n=40) | |
| Age, y | 81.7±6.9 |
| Male sex | 16 (40) |
| EuroSCORE II, % | 4.8±2.4 |
| <4% | 16 (40) |
| 4% to 10% | 24 (60) |
| STS, % | 5.1±2.5 |
| <4% | 13 (32.5) |
| 4% to 10% | 27 (67.5) |
| Frailty index | 0.2±0.1 |
| Previous mediastinal radiation | 0 (0) |
| Chest deformity | 0 (0) |
| Porcelain aorta | 1 (2.5) |
| Carotid disease >50% | 7 (17.5) |
| Stroke | 6 (15) |
| BMI, kg/m2 | 29.1±6.7 |
| Hypertension | 30 (75) |
| Hyperlipidemia | 34 (85) |
| Diabetes mellitus | 14 (35) |
| Creatinine >150 μmol/L | 6 (15) |
| Chronic liver failure or cirrhosis | 0 (0) |
| Significant (>5 pack years) smoking | 15 (37.5) |
| NYHA III or IV | 32 (80) |
| LVEF, % | 59.3±9.6 |
| LVEF ≤50% | 4 (10) |
| LVEF ≤35% | 0 (0) |
| Aortic valve area, cm2 | 0.8±0.2 |
| Mean AV gradient, mmHg | 46.1±10.6 |
| Peak AV jet velocity, m/s | 4.3±0.4 |
| Atrial fibrillation | 11 (27.5) |
| Procedural characteristics (n=40) | |
| Access approach | |
| Transfemoral | 20 (50) |
| Transaortic | 14 (35) |
| Transapical | 6 (15) |
| Device success | 38 (95) |
| Average procedure time, minutes | 71.4±18.4 |
| Fluoroscopic time, minutes | 14.3±8.5 |
| Fluoroscopy contrast volume, mL | 148.9±46.2 |
| Rapid ventricular pacing duration, seconds | 30.3±15.9 |
| ACT at deployment, seconds | 333±49.5 |
Values are expressed as mean±standard deviation or as n (%). ACT indicates activated clotting time; AV, aortic valve; BMI, body mass index; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; STS, Society of Thoracic Surgeons.